Hepar Lobatum Carcinomatosum: Risk of Underestimated Progression in a Triple Negative Metastatic Breast Cancer

Morcet-Delattre Robin1, Zimmermann Pierre-André2, Lesourd Samuel1 and Billard Felix1, LE DU Fanny1*

1Department of Medical Oncology, Eugène Marquis Cancer Center, France 2Department of Nuclear Medicine, Eugène Marquis Cancer Center, France 3Department of Radiology, CHU, France

^*Correspondance to: LE DU Fanny 

 PDF  Full Text Case Report | Open Access

Abstract:

A 49-year-old woman with metastatic triple-negative breast cancer with liver metastasis died, during her systemic chemotherapy treatment of a liver dysfunction (hepatic cytolysis, portal hypertension and hepatic dysmorphism) despite clear decrease in metabolism on PET-CT images. This patient suffered from a Hepar Lobatum Carcinomatosum (HL) or pseudocirrhosis which is an acquired non-cirrhotic major hepatic dysmorphism mostly observed during systemic treatments of liver metastatic breast carcinoma patients. Sinusoidal obstruction syndrome is the main mechanism of HL. The radiological aspect is well described in the literature unlike the metabolic aspect on PET-CT images as presented here with a confusing partial metabolic response.

Keywords:

Cite the Article:

Robin M-D, Pierre-André Z, Samuel L, Felix B, Fanny LD. Hepar Lobatum Carcinomatosum: Risk of Underestimated Progression in a Triple Negative Metastatic Breast Cancer. Ann Clin Case Rep. 2022; 7: 2217..